Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

110.86 USD -0.40 (-0.36%)
Official Closing Price Updated: 7:52 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Biotech Is Fueling An All-New Cannabis Boom
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Is Fueling An All-New Cannabis Boom
- FN Media Group Presents Safehaven.com Market Commentary 
From PR Newswire
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
- BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications 
From PR Newswire
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma
From GlobeNewswire News Releases
Allergan Aesthetics Enters Into Option to Acquire Cypris Medical
-- Agreement Includes Development of Xact Device, a Minimally-Invasive Alternative Option for Performing Face and Neck Lifts -- 
From PR Newswire
Researchers Seek to Better Understand Psychedelics' Role in New Therapies
FinancialBuzz.com News Commentary 
From PR Newswire
AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. AbbVie will host a live webcast of the earnings... 
From PR Newswire
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced that AbbVie (NYSE: ABBV), has... 
From PR Newswire
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
- A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab (600 mg or 1200 mg) achieved both primary endpoints, demonstrating statistically... 
From PR Newswire
AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's executive leadership team will present virtually at 3:30 p.m.... 
From PR Newswire
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo... 
From PR Newswire
IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (WM)
- Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab... 
From PR Newswire
CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
- Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS),... 
From PR Newswire
RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
- 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1] 
From PR Newswire
Upadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis
- Significantly more upadacitinib-treated (45 mg) patients achieved clinical remission (primary endpoint per Adapted Mayo Score) at week 8 compared to placebo in adults with moderate to severe... 
From PR Newswire
Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low
AbbVie (NYSE: ABBV), today announced results from a long-term integrated analysis of two Phase 3 clinical studies and additional pooled analysis evaluating the effect of IMBRUVICA (ibrutinib) based... 
From PR Newswire
AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)
- New five-year, follow-up analysis from the Phase 3 MURANO trial shows median progression-free survival (PFS) of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in... 
From PR Newswire
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic L
AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax) in previously... 
From PR Newswire
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
- Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases 
From PR Newswire
AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
- Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases 
From PR Newswire
AbbVie to Host Virtual Immunology Strategic Update
AbbVie (NYSE: ABBV) will host a virtual immunology strategic update for investors on Monday, December 14, 2020 at 9:00 a.m. Central time. Richard A. Gonzalez, chairman of the board and chief executive... 
From PR Newswire
This Ancient Aztec Medicine Could Be A Gamechanger For Mental Health
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
This Ancient Aztec Medicine Could Be A Gamechanger For Mental Health
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary 
From PR Newswire
AbbVie to Present at the Evercore ISI Conference and Piper Sandler Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Evercore ISI Virtual HealthCONx Conference on Wednesday, December 2 at 1:40 p.m. CT and the Piper Sandler Virtual Healthcare Conference on Thursday, December... 
From PR Newswire
AbbVie Announces Expiration and Final Results of Registered Exchange Offers
AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the expiration and final results of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $30,000,000,000... 
From PR Newswire
Banking on the Next Blockbuster Drug
From InvestorBrandNetwork
Allergan Aesthetics Celebrates Second Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
NUMBER 1 SELLING PRODUCT OF ITS KIND CELEBRATES BOTH LOYAL AND NEW CONSUMERS WITH EXCLUSIVE OFFER ON NOVEMBER 18th 
From PR Newswire
AbbVie to Present at the Wolfe Research Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Thursday, November 19, 2020. Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive... 
From PR Newswire
On the Trail of Better Therapeutics for Depression
From InvestorBrandNetwork
On the Trail of Better Therapeutics for Depression
NetworkNewsWire Editorial Coverage 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.